Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | GRK2 | P25098 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30293244 | 1.00 | CHRM2 (0.50) | CHRM2RAB9APOLBCA1CA2 | |
| SCHEMBL430528 | 0.79 | TP53 (0.60) | RAB9ACA1CA2CA9SMN1; SMN2 | |
| SCHEMBL10499428 | 0.79 | HSD17B10 (0.50) | CHRM2RAB9APOLBCA1CA2 | |
| SCHEMBL16964497 | 0.78 | RAB9A (0.47) | RAB9ACA1CA2CA9XDH | |
| SCHEMBL2675404 | 0.78 | ALDH1A1 (0.68) | RAB9APOLBSMN1; SMN2NPC1TDP1 | |
| SCHEMBL2317747 | 0.75 | XDH (0.51) | CHRM2RAB9AXDHSLC22A12SMN1; SMN2 | |
| SCHEMBL23417745 | 0.74 | POLB (0.51) | RAB9APOLBALDH1A1GAAMAPT | |
| SCHEMBL31198179 | 0.74 | HDAC1 (0.60) | RAB9APOLBCA1CA2CA9 | |
| SCHEMBL2767464 | 0.74 | HDAC1 (0.60) | RAB9APOLBCA1CA2CA9 | |
| SCHEMBL27562807 | 0.74 | KIF11 (0.58) | CHRM2RAB9ACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024049976-A1 | N-METHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE COMPOUNDS | ABBVIE INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2024049976-A1 | N-METHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE COMPOUNDS | ABBVIE INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| CN-109988093-B | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine | 广东东阳光药业有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-9856219-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160340312-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2016-11-24 | — | — | US | disclosed |
| US-9433618-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160220556-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2016-08-04 | — | — | US | disclosed |
| US-9315462-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| EP-2977050-A1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | Nivalis Therapeutics, Inc. (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20150336897-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2015-11-26 | — | — | US | disclosed |
| EP-2624695-B1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | NIVALIS THERAPEUTICS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| US-9139528-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150080429-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2015-03-19 | — | — | US | disclosed |
| US-8921562-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2624695-A1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20130178499-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| CN-103200820-A | Novel substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS LLC | 2013-07-10 | — | — | CN | disclosed |
| WO-2012170371-A1 | COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012048181-A1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340312-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | CHRM2 1833/4885RAB9A 2639/4885POLB 1735/4885 |
| US-20130178499-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | CHRM2 1833/4885RAB9A 2639/4885POLB 1735/4885 |
| US-20150336897-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | CHRM2 1833/4885RAB9A 2639/4885POLB 1735/4885 |
| US-20150080429-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | CHRM2 1833/4885RAB9A 2639/4885POLB 1735/4885 |
| US-20160220556-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | CHRM2 1833/4885RAB9A 2639/4885POLB 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.